Angion Biomedica Overview

  • Founded
  • 1998
Founded
  • Status
  • Public
  • Employees
  • 53
Employees
  • Stock Symbol
  • ANGN
Stock Symbol
  • Investments
  • 2
  • Share Price
  • $3.75
  • (As of Friday Closing)

Angion Biomedica General Information

Description

Angion Biomedica Corp is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading with ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Contact Information

Website
www.angion.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
  • 1700 Montgomery Street
  • Suite 108
  • San Francisco, CA 94111
  • United States
+1 (415) 000-0000

Angion Biomedica Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Angion Biomedica Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.75 $3.98 $3.64 - $26.30 $112M 30M 277K -$4.22

Angion Biomedica Financials Summary

In Thousands,
USD
TTM 30-Sep-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 178,596
Revenue 2,830 2,880 1,487 4,029
EBITDA (90,079) (70,633) (40,427) (20,275)
Net Income (98,338) (80,107) (40,658) (20,025)
Total Assets 109,940 47,347 11,886 26,628
Total Debt 4,576 56,523 10,778 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Angion Biomedica Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Angion Biomedica‘s full profile, request access.

Request a free trial

Angion Biomedica Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Angion Biomedica‘s full profile, request access.

Request a free trial

Angion Biomedica Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Angion Biomedica Corp is a late-stage biopharmaceutical company focused on the discovery, development and commercializat
Drug Discovery
San Francisco, CA
53 As of 2021
00000
000000000 00000

0000000

tion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
0000 000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000

00-00000

or in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint o
0000 000000000
Utrecht, Netherlands
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Angion Biomedica Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tricida Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
00-000000 Venture Capital-Backed Utrecht, Netherlands 00 00000 000000 - 000 00000
000000 00000000000 Formerly VC-backed Cambridge, MA 000 00000 000000 - 000 00000
000000000 00000000 Venture Capital-Backed Hennigsdorf, Germany 0 00.000 0000000000 00.000
00000000000 Formerly PE-Backed Cary, NC 000 000.00 000000000000
You’re viewing 5 of 17 competitors. Get the full list »

Angion Biomedica Patents

Angion Biomedica Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200369654-A1 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole Granted 11-Apr-2019 0000000000
US-10875849-B2 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole Active 11-Apr-2019 0000000000 00
US-20210078984-A1 Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole Pending 11-Apr-2019 0000000000
US-20180148438-A1 Cytochrome p450 inhibitors and uses thereof Granted 29-Nov-2016 0000000000 0
US-10414760-B2 Cytochrome p450 inhibitors and uses thereof Active 29-Nov-2016 C07D417/06 0

Angion Biomedica Executive Team (8)

Name Title Board Seat Contact Info
Jay Venkatesan MD Chief Executive Officer, President and Board Member
Gregory Curhan Chief Financial Officer, Finance
Itzhak Goldberg MD Chairman & Chief Scientific Officer
Jennifer Rhodes JD General Counsel, Legal & Secretary, Administration
John Neylan MD Chief Medical Officer & Senior Vice President
You’re viewing 5 of 8 executive team members. Get the full list »

Angion Biomedica Board Members (7)

Name Representing Role Since
Allen Nissenson MD Self Board Member 000 0000
Allen Nissenson MD Angion Biomedica Board Member 000 0000
Gilbert Omenn Ph.D Angion Biomedica Board Member 000 0000
Itzhak Goldberg MD Angion Biomedica Chairman & Chief Scientific Officer 000 0000
Karen Wilson Angion Biomedica Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Angion Biomedica Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Angion Biomedica Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Angion Biomedica‘s full profile, request access.

Request a free trial

Angion Biomedica Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 01-Jul-2017 000000000 Personal Products
Ohr Cosmetics 15-Nov-2013 Corporate 00000 Personal Products
To view Angion Biomedica’s complete investments history, request access »